NasdaqGM:JANXBiotechs
Janux Therapeutics JANX Net Loss Deepens To US$113.6 Million Challenging Bullish Growth Narratives
Janux Therapeutics (JANX) closed out FY 2025 with Q4 revenue of US$0 and a basic EPS loss of US$0.51, keeping the focus squarely on how efficiently it is funding and progressing its pipeline rather than on top line growth. The company has seen quarterly revenue move between US$0 and US$10 million over the past year, while basic EPS losses have ranged from US$0.38 to US$0.55 per share. This sets up a story in which any potential upside depends heavily on whether management can convert this...